CN101028315A - Chinese medicine for treating neuralgia - Google Patents
Chinese medicine for treating neuralgia Download PDFInfo
- Publication number
- CN101028315A CN101028315A CN 200610171355 CN200610171355A CN101028315A CN 101028315 A CN101028315 A CN 101028315A CN 200610171355 CN200610171355 CN 200610171355 CN 200610171355 A CN200610171355 A CN 200610171355A CN 101028315 A CN101028315 A CN 101028315A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- leyss
- karst
- neuralgia
- ganoderma lucidum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 208000004296 neuralgia Diseases 0.000 title description 9
- 240000008397 Ganoderma lucidum Species 0.000 claims description 12
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 12
- 241001480581 Marasmius Species 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 3
- 208000004929 Facial Paralysis Diseases 0.000 abstract description 4
- 206010050031 Muscle strain Diseases 0.000 abstract description 4
- 208000008765 Sciatica Diseases 0.000 abstract description 4
- 208000036826 VIIth nerve paralysis Diseases 0.000 abstract description 4
- 201000003068 rheumatic fever Diseases 0.000 abstract description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 abstract description 4
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 241000222336 Ganoderma Species 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010061363 Skeletal injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 206010072132 Fracture pain Diseases 0.000 description 3
- 206010024229 Leprosy Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 210000001097 facial muscle Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000002061 histotrophic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine for treating the pain caused by bone fracture and injury, ischias, trigeminal neuralgia, hemicrania, facial paralysis, lumbar muscle strain, rheumatic arthritis, etc is prepared from 2 Chinese-medicinal materials including red ganoderma through decocting.
Description
Technical field
The present invention relates to the neuralgic Chinese medicine of a kind of treatment.
Background technology
At present, the medicine of state internal therapy neuralgia aspect is a lot, but in Chinese medicine, the Chinese medicine that the treatment works well seldom can not reach the therapeutic effect that treatment combines with functional rehabilitation.The present invention wishes to find a reasonable medicine in treatment neuralgia aspect.
Summary of the invention
The purpose of this invention is to provide the neuralgic Chinese medicine of a kind of treatment, and easy to use, can reach the therapeutic effect that treatment combines with functional rehabilitation.
The weight proportion of Chinese medicine medicinal raw material of the present invention consists of Marasmius equicrinis Muell. 5～80, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 5～60.The optimum weight proportioning of each component is a Marasmius equicrinis Muell. 25, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 20.
Marasmius equicrinis Muell.: little hardship, temperature.Can invigorate blood circulation, dispel the wind, collateral dredging, hemostasis.Be used for diseases such as traumatic injury, fracture pain, sciatica, trigeminal neuralgia, migraine, supraorbital neuralgia, leprosy neuralgia, facial paralysis, facial muscle meat spasm, lumbar muscle strain, rheumatic arthritis.Can promote the inflammation of nervous tissue and fibrous connective tissue to disappear, improve partial blood circulation and histotrophic nutrition situation, recover function of nervous system.(" Chinese medicinal cryptogam ") is respectively 60% and 70% to the suppression ratio of white mice sarcoma 180, ehrlich carcinoma.
Ganoderma lucidum (Leyss. Ex Fr.) Karst.: sweet, light, bitter in the mouth is flat, nontoxic.The energy invigorating the lung and the kidney, stomach function regulating spleen invigorating, tranquilizing the mind, the body resistance strengthening and constitution consolidating.With controlling asthenia cough with asthma, palpitation and insomnia, inappetence, be used for the treatment of diseases such as coronary heart disease, angina pectoris, hypertension, hyperlipidemia, myocarditis, leukopenia, hepatitis, gastric and duodenal ulcers, diabetes, progressive muscular dystrophy, multiple sclerosis in recent years.Protect the liver and Detoxication, (1) has tangible reduction effect to rising and the accumulating of liver triacylglycerol of sGPT; (2) can alleviate dealed with medicine went to hepatotoxicity; (3) promote the hepatectomize liver regeneration reparation of mice of part; (4) can make the tangible immune restoration effect of cytochrome content in the liver homogenate.
The object of the present invention is achieved like this:
Contain Marasmius equicrinis Muell., Ganoderma lucidum (Leyss. Ex Fr.) Karst. in the neuralgic Chinese medicine of treatment of the present invention.
The weight proportion of described each component is a Marasmius equicrinis Muell. 5～80, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 5～60.
The optimum weight proportioning of described each component is a Marasmius equicrinis Muell. 25, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 20.
Marasmius equicrinis Muell. 5～80g, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 5～60g, this is a dosage.
During use, with Marasmius equicrinis Muell., Ganoderma lucidum (Leyss. Ex Fr.) Karst. shreds by a dosage, adds the 500g decocting and obeys to 150g, day clothes 2 times.Can control diseases such as traumatic injury, fracture pain, sciatica, trigeminal neuralgia, migraine, supraorbital neuralgia, leprosy neuralgia, facial paralysis, facial muscle meat spasm, lumbar muscle strain, rheumatic arthritis.
The invention has the beneficial effects as follows: raw material is simple, can effectively control diseases such as traumatic injury, fracture pain, sciatica, trigeminal neuralgia, migraine, supraorbital neuralgia, leprosy neuralgia, facial paralysis, facial muscle meat spasm, lumbar muscle strain, rheumatic arthritis.
The specific embodiment
Get Marasmius equicrinis Muell. 25g, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 20g shreds, and adds the 500g decocting and obeys to 150g, day clothes 2 times.
Get Marasmius equicrinis Muell. 20g, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 15g shreds, and adds the 500g decocting and obeys to 150g, day clothes 2 times.
Claims (2)
1, the neuralgic Chinese medicine of a kind of treatment, it is characterized in that: the weight proportion of this Chinese medicine medicinal raw material consists of Marasmius equicrinis Muell. 5～80, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 5～60.
2, the neuralgic Chinese medicine of treatment according to claim 1 is characterized in that: the optimum weight proportioning of each component is a Marasmius equicrinis Muell. 25, Ganoderma lucidum (Leyss. Ex Fr.) Karst. 20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610171355 CN101028315A (en) | 2006-12-17 | 2006-12-17 | Chinese medicine for treating neuralgia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610171355 CN101028315A (en) | 2006-12-17 | 2006-12-17 | Chinese medicine for treating neuralgia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101028315A true CN101028315A (en) | 2007-09-05 |
Family
ID=38713966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610171355 Pending CN101028315A (en) | 2006-12-17 | 2006-12-17 | Chinese medicine for treating neuralgia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101028315A (en) |
-
2006
- 2006-12-17 CN CN 200610171355 patent/CN101028315A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1072938C (en) | Traditional chinese medicine for curing gastric disease | |
| CN1272057C (en) | Chinese traditional medicine for treating facial paralysis, facial spasm and trifacial neuralgia | |
| CN1589881A (en) | Chinese medicinal prescription for treating gastropathy | |
| CN101028334A (en) | Chinese medicine for treating chronic tonsillitis | |
| CN1698877A (en) | Liver nourishing capsule with Chinese caterpillar fungus | |
| CN1555829A (en) | Chinese medicinal preparation for treating cancer | |
| CN101028315A (en) | Chinese medicine for treating neuralgia | |
| CN1197594C (en) | Brain and heart recovery pill | |
| CN101028300A (en) | Chinese medicine for treating rheumatic arthralgia | |
| CN101028293A (en) | Chinese medicine for treating esophagus cancer, stomach cancer and uterine cancer | |
| CN1785276A (en) | Medicine for treating atrophic arthritis | |
| CN101028306A (en) | Chinese medicine for treating chronic dementia praecox | |
| CN101028297A (en) | Chinese medicine for treating hepatic hepatic hydroperitonia | |
| CN101028307A (en) | Chinese medicine for treating liver hydroperitoneum | |
| CN101011425A (en) | Traditional Chinese medicine for treating esophagus cancer, gastric cancer, uterocarcinoma and hysteromyoma | |
| CN1070709C (en) | Chinese drug preparation for curing hepatopathy and its preparation | |
| CN1279977A (en) | Chinese medicine preparation for curing rheumatic arthritis and its preparing method | |
| CN1245210C (en) | Ready made traditional Chinese medicine for treating hyperplasia of mammary glans | |
| CN1054052C (en) | Comedo-elimination preparation | |
| CN101028296A (en) | Chinese medicine for treating tumor | |
| CN1403143A (en) | Composite Chinese medicine for treating gastrointestinal diseases | |
| CN1273834A (en) | Chinese medicine for treating rheumatism | |
| CN101028303A (en) | Chinese medicine for treating hypertension | |
| CN101011430A (en) | Chinese traditional medicine for treating rheumatoid arthralgia and paralysis of hand and foot | |
| CN101028299A (en) | Chinese medicine for treating cardiopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Tian Zhi Shen wild Ganoderma lucidum science and Technology Research Institute Assignor: Chen Kanglin Contract fulfillment period: 2007.11.6 to 2024.12.10 contract change Contract record no.: 2007990000093 Denomination of invention: Chinese medicine for treating neuralgia Granted publication date: Wei Shouquan License type: Exclusive license, sub license Record date: 2007.12.3 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.11.6 TO 2024.12.10 Name of requester: BEIJING TIAN-ZHI HUASHEN WILD GANODERMA LUCIDUM S Effective date: 20071203 |
|
| ASS | Succession or assignment of patent right |
Owner name: SHI HAIYAN Free format text: FORMER OWNER: CHEN KANGLIN Effective date: 20080718 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080718 Address after: Room 717, B block, 27 international capital center, South Binhe Road, Beijing, Xuanwu District, China: 100055 Applicant after: Shi Haiyan Address before: 7, Liyuan villa, South long Kun Road, Hainan, Haikou Province, China: 570000 Applicant before: Chen Kanglin |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |